Media Summary: Dr. Kantor talks with Dr. Tony Reder and answers the question, " Dr. Robert Chao discusses abstract L15 presented at ACR22 Convergence. Selecting the right therapy in axial spondyloarthritis requires more than symptom control—it requires structured monitoring and ...

Should I Have Interleukin 17 Tested - Detailed Analysis & Overview

Dr. Kantor talks with Dr. Tony Reder and answers the question, " Dr. Robert Chao discusses abstract L15 presented at ACR22 Convergence. Selecting the right therapy in axial spondyloarthritis requires more than symptom control—it requires structured monitoring and ... This video explains the regulatory mechanisms that control autoreactive th17 cells & IL- Psoriasis is a chronic inflammatory skin disorder that affects about 2-3% of the population. It is triggered by the immune system, ... Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 ...

In this interview, Neal Bhatia, MD, the director of Clinical Dermatology at Therapeutics Clinical Research, Bhatia was asked about ... Welcome to this FAQ video module, proudly supported by Johnson & Johnson. In this educational session, Erica Heagy, NP, from ... Dive into the compelling universe of immunology with our succinct overview of

Photo Gallery

Should I Have Interleukin 17 Tested
Which is better for AxSpA? IL-17i or TNFi?
Laura K. Ferris, MD, PhD - Do IL-17 inhibitors work more quickly than IL-23 inhibitors and what...
Choosing Between TNF, IL 17, and JAK Inhibitors in Axial Spondyloarthritis – Dr. Jill Weintraub
WCH23: IL-17 vs IL-23 Blockers – Why and When?
Family Matters: The Central Role of the IL-17 Family of Cytokines in Inflammatory Disease
Dr Naglaa Elmongy//How IL17 is regulated to avoid cytokine storm, autoimmune & inflammatory disease
Psoriasis and beyond: targeting the IL-17 pathway
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Discussing GLP-1 or Dual Incretin Therapies in IL-17 Mediated Disease, With Neal Bhatia, MD
FAQ: Describe the IL23/IL17 axis
Unlocking the Secrets of IL17A: The Guardian of Immunity and Mediator of Inflammation
Sponsored
Sponsored
View Detailed Profile
Should I Have Interleukin 17 Tested

Should I Have Interleukin 17 Tested

Dr. Kantor talks with Dr. Tony Reder and answers the question, "

Which is better for AxSpA? IL-17i or TNFi?

Which is better for AxSpA? IL-17i or TNFi?

Dr. Robert Chao discusses abstract L15 presented at ACR22 Convergence.

Sponsored
Laura K. Ferris, MD, PhD - Do IL-17 inhibitors work more quickly than IL-23 inhibitors and what...

Laura K. Ferris, MD, PhD - Do IL-17 inhibitors work more quickly than IL-23 inhibitors and what...

Laura K. Ferris, MD, PhD -

Choosing Between TNF, IL 17, and JAK Inhibitors in Axial Spondyloarthritis – Dr. Jill Weintraub

Choosing Between TNF, IL 17, and JAK Inhibitors in Axial Spondyloarthritis – Dr. Jill Weintraub

Selecting the right therapy in axial spondyloarthritis requires more than symptom control—it requires structured monitoring and ...

WCH23: IL-17 vs IL-23 Blockers – Why and When?

WCH23: IL-17 vs IL-23 Blockers – Why and When?

Dermatologists

Sponsored
Family Matters: The Central Role of the IL-17 Family of Cytokines in Inflammatory Disease

Family Matters: The Central Role of the IL-17 Family of Cytokines in Inflammatory Disease

... joint inflammation without 17b there

Dr Naglaa Elmongy//How IL17 is regulated to avoid cytokine storm, autoimmune & inflammatory disease

Dr Naglaa Elmongy//How IL17 is regulated to avoid cytokine storm, autoimmune & inflammatory disease

This video explains the regulatory mechanisms that control autoreactive th17 cells & IL-

Psoriasis and beyond: targeting the IL-17 pathway

Psoriasis and beyond: targeting the IL-17 pathway

Psoriasis is a chronic inflammatory skin disorder that affects about 2-3% of the population. It is triggered by the immune system, ...

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?

Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 ...

Discussing GLP-1 or Dual Incretin Therapies in IL-17 Mediated Disease, With Neal Bhatia, MD

Discussing GLP-1 or Dual Incretin Therapies in IL-17 Mediated Disease, With Neal Bhatia, MD

In this interview, Neal Bhatia, MD, the director of Clinical Dermatology at Therapeutics Clinical Research, Bhatia was asked about ...

FAQ: Describe the IL23/IL17 axis

FAQ: Describe the IL23/IL17 axis

Welcome to this FAQ video module, proudly supported by Johnson & Johnson. In this educational session, Erica Heagy, NP, from ...

Unlocking the Secrets of IL17A: The Guardian of Immunity and Mediator of Inflammation

Unlocking the Secrets of IL17A: The Guardian of Immunity and Mediator of Inflammation

Dive into the compelling universe of immunology with our succinct overview of

Target of the Month: Interleukin-17

Target of the Month: Interleukin-17

Interleukin